Infinity Bio MIPSA Explainer

Antibodies serve as a detailed ledger of past and ongoing immune responses, presenting a crucial window into health and disease mechanisms. At Infinity Bio, we decode the molecular portfolio of potential antibody targets, which is known as the antibody reactome.

Our novel MIPSA technology is used to generate very large panels of DNA-barcoded full-length protein antigens and/or rationally designed peptide antigens. These panels — referred to as antigen libraries — cover entire proteomic spaces, including all viral, allergen, and non-viral microbes in human proteins.

A MIPSA antigen library is mixed with a biospecimen containing antibodies, allowing the antibodies to bind their targets in solution. These antibody-bound antigens are then captured and identified by sequencing of their unique DNA barcodes. Our bioinformatics pipeline quantifies each antigen reactivity against a set of controls.

Infinity Bio’s MIPSA technology delivers a comprehensive picture of an individual’s antibody reactome with unprecedented accuracy, and immune responses can now be associated with key health outcomes at population scale.

Interested in the interplay of environment, inflammation, and immunity? Connect with us at infinitybio.com/contact.